TY - JOUR
T1 - Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli
T2 - Results of the CANWARD 2007-2009 study
AU - Simner, Patricia J.
AU - Zhanel, George G.
AU - Pitout, Johann
AU - Tailor, Franil
AU - McCracken, Melissa
AU - Mulvey, Michael R.
AU - Lagacé-Wiens, Philippe R.S.
AU - Adam, Heather J.
AU - Hoban, Daryl J.
N1 - Funding Information:
Patricia Simner is supported by the Natural Sciences and Engineering Research Council. Funding and medical center (investigator) acknowledgements are provided in the first paper of this symposium ( Hoban and Zhanel, 2011 ).
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/3
Y1 - 2011/3
N2 - The national prevalence of extended-spectrum β-lactamase (ESBL)-producing (2007: 3.4%, 2008: 4.9%, 2009: 4.3%) and AmpC β-lactamase (AmpC)-producing (2007: 0.8%, 2008: 3.2%, 2009: 2.7%) Escherichia coli in Canadian hospitals have fluctuated from 2007 to 2009. Rates of co-resistance to non-lactam agents are elevated, and multidrug-resistant (MDR) phenotype were observed among E. coli strains producing ESBLs (83.3% MDR) and AmpCs (31.0%). The majority (>98%) of isolates remained susceptible to colistin, tigecycline, amikacin, and the carbapenems. CMY-2 encoding gene was detected in 52.9% of AmpC-producing strains, while blaCTX-M-15 (65.2%) was the predominant ESBL genotype. A total of 50.3% of ESBL-producing E. coli and 21.4% of AmpC producers belonged to the ST131 clone. In conclusion, ESBL- and AmpC-producing E. coli are established in Canadian hospitals; and although the prevalence rates of these isolates remain low, they are often MDR and associated with the ST131 clone.
AB - The national prevalence of extended-spectrum β-lactamase (ESBL)-producing (2007: 3.4%, 2008: 4.9%, 2009: 4.3%) and AmpC β-lactamase (AmpC)-producing (2007: 0.8%, 2008: 3.2%, 2009: 2.7%) Escherichia coli in Canadian hospitals have fluctuated from 2007 to 2009. Rates of co-resistance to non-lactam agents are elevated, and multidrug-resistant (MDR) phenotype were observed among E. coli strains producing ESBLs (83.3% MDR) and AmpCs (31.0%). The majority (>98%) of isolates remained susceptible to colistin, tigecycline, amikacin, and the carbapenems. CMY-2 encoding gene was detected in 52.9% of AmpC-producing strains, while blaCTX-M-15 (65.2%) was the predominant ESBL genotype. A total of 50.3% of ESBL-producing E. coli and 21.4% of AmpC producers belonged to the ST131 clone. In conclusion, ESBL- and AmpC-producing E. coli are established in Canadian hospitals; and although the prevalence rates of these isolates remain low, they are often MDR and associated with the ST131 clone.
KW - AmpC
KW - E. coli
KW - ESBL
UR - http://www.scopus.com/inward/record.url?scp=79951888752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951888752&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2010.10.029
DO - 10.1016/j.diagmicrobio.2010.10.029
M3 - Article
C2 - 21353961
AN - SCOPUS:79951888752
SN - 0732-8893
VL - 69
SP - 326
EP - 334
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 3
ER -